Notably, HER2+ breast cancer is characterized by the sustained activation of HER2 signaling, which has been successfully exploited for selective targeted therapy by monoclonal antibodies, such as trastuzumab (2). This evidence concerns the gene ERBB2 and breast carcinoma.